Imagen de Portada

Sodium‐glucose cotransporter‐2 inhibitors and the risk of lung cancer among patients with type 2 diabetes

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Samantha B. Shapiro, Hui Yin, Oriana H. Y. Yu, Laurent Azoulay
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	British Journal of Clinical Pharmacology
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Sodium–glucose cotransporter 2 inhibitor increases risk of urinary tract infection: Evidence from mendelian randomization and meta‐analysis
por: Jie Ren, et al.
Publicado: (2025)

Cardiovascular benefits of early sodium‐glucose cotransporter 2 inhibitor use for diabetics with acute myocardial infarction: A nationwide cohort study
por: Sheng‐Fan Wang, et al.
Publicado: (2025)

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users
por: Haoxin Le, et al.
Publicado: (2026)

Prevalence of potentially inappropriate medications among newly treated patients with type 2 diabetes in UK primary care
por: Maria Luisa Faquetti, et al.
Publicado: (2024)

Pharmacokinetics and pharmacodynamics of empagliflozin in paediatric patients aged 10–17 years with type 2 diabetes mellitus
por: Juliane Rascher, et al.
Publicado: (2025)

Antidepressant and antipsychotic prescribing in patients with type 2 diabetes in Scotland: A time‐trend analysis from 2004 to 2021
por: Charlotte R. L. Greene, et al.
Publicado: (2024)

Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus
por: Hongtao Yu, et al.
Publicado: (2025)

Efficacy and safety of androgen receptor inhibitors for treatment of advanced prostate cancer: A systematic review and network meta‐analysis
por: Shichao Xiao, et al.
Publicado: (2024)

Quantitative prediction of intravenous drug interactions caused by cytochromes P450 inhibitors and inducers
por: Vianney Tuloup, et al.
Publicado: (2026)

Effect of food on pharmacokinetics of ACC017, a novel HIV‐1 integrase inhibitor, in healthy adult subjects
por: C. Hu, et al.
Publicado: (2025)

Exposure–response relationship of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis
por: Yizhe Chen, et al.
Publicado: (2025)

Single‐dose pharmacokinetics and safety of ACC017, a novel HIV integrase inhibitor, in healthy adult participants: A first‐in‐human study
por: C. Hu, et al.
Publicado: (2025)

Development of a predictive model for neutropenia risk in Japanese breast cancer patients treated with doxorubicin and cyclophosphamide
por: Takehiro Miyagi, et al.
Publicado: (2025)

The association between use of proton pump inhibitors and frailty index among middle‐aged and older adults
por: Rui Wu, et al.
Publicado: (2024)

AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma
por: Anna Lundahl, et al.
Publicado: (2025)

SLCO1B1 variants in a patient of African ancestry presenting with rosuvastatin‐induced rhabdomyolysis: A case report
por: Samantha Medwid, et al.
Publicado: (2024)

Assessing the applicability of the DOAC, HAS‐BLED and ORBIT risk scores in Chinese patients on non‐vitamin K antagonist oral anticoagulants
por: Miao Fan, et al.
Publicado: (2025)

Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants
por: Mohammad Ghasemi, et al.
Publicado: (2025)

Best fit framework synthesis of qualitative studies on factors associated with medication nonadherence in people with type 2 diabetes using the COM‐B model
por: Vivien Teo, et al.
Publicado: (2025)

Cost–utility analysis of sotagliflozin for heart failure patients with diabetes in China
por: Xinyue Zhang, et al.
Publicado: (2025)

A phase 1 trial of AP30663, a KCa2 channel inhibitor in development for conversion of atrial fibrillation
por: Christina Yfanti, et al.
Publicado: (2024)

Why and how do we perform physical examination(s) in clinical trials? A use case of drug intervention trials in type 2 diabetes mellitus
por: Julia Kopanz, et al.
Publicado: (2025)

Predicting potassium trajectories for risk monitoring in outpatients with heart failure, diabetes mellitus or chronic kidney disease
por: Camilo Scherkl, et al.
Publicado: (2025)

Bleeding in patients on concurrent treatment with serotonin reuptake inhibitor (SRI) and acetylsalicylic acid (ASA) compared with ASA alone: a pharmacovigilance study
por: Jean‐Louis Montastruc, et al.
Publicado: (2024)

Longitudinal non‐cancer pain management patterns and risk of adverse outcomes in older adults: Insights from group‐based multi‐trajectory modelling
por: I‐Tzu Chen, et al.
Publicado: (2025)

Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies
por: Sebastiaan van Kraaij, et al.
Publicado: (2024)

Semaglutide use is associated with neuromuscular junction degradation in older adults with type II diabetes mellitus
por: Rizwan Qaisar, et al.
Publicado: (2025)

Safe and supportive prescribing in transgender and non‐binary patients with cancer
por: Mariachiara D'Elia, et al.
Publicado: (2024)

Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer
por: Catharina J. P. Op 't Hoog, et al.
Publicado: (2025)

Co‐prescription of low‐dose methotrexate and trimethoprim‐sulfamethoxazole and the 30‐day risk of death among older adults: A cohort study
por: Hasti Sadeghi, et al.
Publicado: (2024)

Cost–utility of lifileucel in patients with advanced melanoma after progression on immune checkpoint inhibitors And targeted therapies: a middle‐income economy setting
por: Svetlana Obrenovic, et al.
Publicado: (2025)

Bleeding in patients on concurrent treatment with a selective serotonin reuptake inhibitor (SSRI) and low‐dose acetylsalicylic acid (ASA) compared with SSRI or low‐dose ASA alone—A systematic review and meta‐analysis
por: Magnus A. B. Axelsson, et al.
Publicado: (2024)

Renoprotective effects of dapagliflozin in diabetic patients with chronic kidney disease: A retrospective observational study
por: Sara Al Lawati, et al.
Publicado: (2026)

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis
por: Andrej Belančić, et al.
Publicado: (2026)

Influence of gut bile acid composition on the glucose‐lowering effect and safety of metformin
por: Deok Yong Yoon, et al.
Publicado: (2024)

Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen
por: Ya‐Ping Tu, et al.
Publicado: (2024)

Comment on ‘Renoprotective effects of dapagliflozin in diabetic patients with chronic kidney disease: A retrospective observational study’
por: Jia Chen, et al.
Publicado: (2026)

Metabolomic investigation of cisplatin‐induced acute kidney injury in paediatric cancer patients
por: Yong Jin Lim, et al.
Publicado: (2026)

Impact of diclofenac risk minimization measures addressing cardiovascular risk on analgesic use in musculoskeletal disorders
por: Tomas Lasys, et al.
Publicado: (2025)

GS‐443902 concentrations in peripheral blood mononuclear cells and dried blood spots among pregnant and non‐pregnant women receiving remdesivir for COVID‐19 treatment
por: A. Dunbar, et al.
Publicado: (2025)